- Home
- GLMD vs CNSP Comparison
GLMD vs CNSP Comparison
Compare GLMD & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | CNSP |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 3.8M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GLMD | CNSP |
|---|---|---|
| Price | $0.67 | $5.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 75.9K | 71.7K |
| Earning Date | 11-26-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $4.93 |
| 52 Week High | $3.50 | $114.00 |
Technical Indicators
Market Signals| Indicator | GLMD | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 33.54 | 36.52 |
| Support Level | $0.66 | $5.76 |
| Resistance Level | $0.87 | $7.51 |
| Average True Range (ATR) | 0.05 | 0.68 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 6.48 | 1.37 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.